7.51
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Risk vs reward if holding onto Sagimet Biosciences Inc.Weekly Investment Recap & Fast Entry Momentum Trade Alerts - newser.com
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences Inc. Announces Participation in Upcoming Investor Conferences - Quiver Quantitative
What technical models suggest about Sagimet Biosciences Inc.’s comeback2025 Key Lessons & Safe Capital Allocation Plans - newser.com
3 Investor Conferences: Sagimet Biosciences to Present Oct–Nov; Fireside chats with 90-day replays - Stock Titan
Phase III met all endpoints: Ascletis completes pre‑NDA consultation with NMPA and plans NDA submission - Stock Titan
What does recent volatility data suggest for Sagimet Biosciences Inc.Weekly Gains Report & Accurate Intraday Trade Tips - newser.com
Will Sagimet Biosciences Inc. stock deliver shareholder value2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
Is Sagimet Biosciences Inc. forming a reversal patternJuly 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Will Sagimet Biosciences Inc. (0O2) stock justify high valuationMarket Sentiment Report & Reliable Price Action Trade Plans - newser.com
Is a relief rally coming for Sagimet Biosciences Inc. holders2025 Biggest Moves & Low Risk High Win Rate Picks - newser.com
Sagimet Biosciences Inc. stock retracement – recovery analysisJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
Sagimet Biosciences (NASDAQ:SGMT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Using flow based indicators on Sagimet Biosciences Inc.July 2025 Decliners & Capital Efficient Trade Techniques - newser.com
Has Sagimet Biosciences Inc. found a price floorAnalyst Upgrade & Stock Market Timing Techniques - newser.com
Developing predictive dashboards with Sagimet Biosciences Inc. dataWeekly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Viking, Genfit, Sagimet jump on Novo- Akero deal (AKRO:NASDAQ) - Seeking Alpha
Sagimet Biosciences' (SGMT) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Sagimet Biosciences Inc. benefit from macro trends2025 Key Lessons & Smart Money Movement Tracker - newser.com
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - GlobeNewswire
≥2‑Stage Fibrosis Improvement: Sagimet denifanstat data to be presented at AASLD 2025 - Stock Titan
Using Ichimoku Cloud for Sagimet Biosciences Inc. technicalsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Why analysts recommend Sagimet Biosciences Inc. (0O2) stock2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com
Using data tools to time your Sagimet Biosciences Inc. exit2025 Risk Factors & Daily Stock Trend Watchlist - newser.com
Is Sagimet Biosciences Inc. stock ready for a breakoutJuly 2025 Final Week & Low Drawdown Trading Strategies - newser.com
Sagimet Biosciences (NASDAQ:SGMT) Given “Buy” Rating at Canaccord Genuity Group - Defense World
Has Sagimet Biosciences Inc. formed a bullish divergenceExit Point & Safe Entry Trade Signal Reports - newser.com
Applying big data sentiment scoring on Sagimet Biosciences Inc.Gap Down & Weekly Market Pulse Alerts - newser.com
Canaccord Genuity Maintains Sagimet Biosciences (SGMT) Buy Recommendation - Nasdaq
Canaccord Genuity Group Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat
Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential - TipRanks
Goldman Sachs Group Inc. Sells 109,464 Shares of Sagimet Biosciences Inc. $SGMT - Defense World
Sagimet Biosciences Inc Stock Analysis and ForecastInsider Selling Patterns & Minimal Investment Portfolio Growth - earlytimes.in
Published on: 2025-10-01 08:26:59 - newser.com
Sagimet Biosciences Inc. Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - MarketScreener
Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom - TipRanks
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):